查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1983695

静脉注射免疫球蛋白市场：按产品类型、患者类型、适应症、最终用户和分销管道分類的全球市场预测，2026-2032年

Intravenous Immunoglobulin Market by Product Type, Patient Type, Indication, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，静脉注射免疫球蛋白市场价值将达到 143.5 亿美元，到 2026 年将成长至 154.2 亿美元，到 2032 年将达到 241.5 亿美元，年复合成长率为 7.72%。

主要市场统计数据
基准年 2025 143.5亿美元
预计年份：2026年 154.2亿美元
预测年份 2032 241.5亿美元
复合年增长率 (%) 7.72%

观点对静脉注射免疫球蛋白如何在不同的临床环境和不断变化的监管要求下支持现代免疫疗法进行了清晰权威的说明。

静脉注射免疫球蛋白在现代免疫疗法中发挥核心作用，是多种临床适应症的重要治疗方法。临床医生依靠这些血浆衍生产品来调节自体免疫疾病、血液系统疾病、免疫力缺乏疾病以及某些神经系统疾病的免疫反应。在现代医疗保健中，静脉注射免疫球蛋白因其作用机制广泛且适用于住院、门诊病人和专科治疗等多种环境而备受重视，其产品系列完美地兼顾了临床紧急治疗和长期疾病管理。

製造技术的创新、临床指南的完善以及监管机构对可追溯性的重视，正在重塑静脉注射免疫球蛋白的供应链和治疗应用。

静脉注射免疫球蛋白领域正经历着一场变革，其驱动力来自生产技术的进步、临床实践的改变以及监管机构对产品来源日益增长的关注。新的生产方法以及纯化和製剂技术的改进降低了不利事件的发生率，延长了产品的保质期，并提供了更稳定的液体製剂。这些都影响着医院的用药决策和门诊给药模式。同时，临床医师正基于不断累积的真实世界数据，不断完善适应症和给药策略，使临床指引与实际应用更加契合。

关税变化对全球血浆采购、生产经济性和免疫球蛋白疗法采购韧性的连锁反应。

关税及相关贸易措施的实施可能会对严重依赖跨境血浆供应和国际生产网络的全球治疗产业产生连锁反应。影响原材料、包装材料或成品的关税调整可能会给采购团队和医院药房带来额外的成本压力，迫使他们重新评估其筹资策略以及与供应商和经销商的合约结构。作为应对措施，企业可能会寻求在地化生产并实现供应商多元化，以降低对单一贸易体系的依赖。

对医疗保健机构、产品配方、患者人口统计特征、分销管道和临床适应症等方面的准入趋势进行全面細項分析。

详细的市场细分揭示了临床需求、製剂偏好和分销管道趋势的交汇点，从而塑造了产品的使用模式。最终使用者因素涵盖居家照护、医院和专科诊所，其中医院又可细分为私立和公立机构，专科诊所则可细分为血液科、免疫科和神经科等科室。这些区分至关重要，因为不同的管理环境会影响管理物流、监测要求和合约方式。私立医院和专科诊所通常与公立医院协商不同的报销和采购条款，居家照护需要与护理服务部门协调，并进行低温运输配送。

影响美洲、欧洲、中东、非洲和亚太地区供应链韧性、监管严格程度和临床引入模式的区域趋势。

区域趋势影响从捐赠血浆到患者的治疗方法流程，每个宏观区域都有其独特的法规、物流和需求面因素。在美洲，完善的血浆采集基础设施、临床医生对静脉注射免疫球蛋白适应症的深刻理解以及先进的医院环境支持了其广泛应用，而区域支付方（保险公司）的政策和采购框架则影响着产品的选择和合约方式。公立和私立医疗保健系统之间的差异、专科诊所的作用以及门诊输液服务的密度都会影响全部区域治疗方法的实施和报销方式。

血浆采购、生产规模和临床证据的策略性投资如何区分主要製造商和分销合作伙伴。

产业相关人员正面临一个复杂的环境，在这个环境中，规模、供应稳定性和合规性至关重要。主要企业正投资于上游工程，例如血浆采集、扩大分馏能力以及加强病原体去除和分析检测，以提高产品的安全性和一致性。血浆采集网路与生产商之间的策略合作日益普遍，旨在确保原材料的稳定供应并降低供应中断的风险。同时，各企业正透过配方技术的进步、涵盖多种适应症的广泛产品系列以及附加价值服务（例如患者支持计划和与输液中心的合作）来实现差异化竞争。

为製造商和供应商提供切实可行的策略措施，以确保供应链安全、增强临床实践机会并优化销售管道。

产业领导企业应采取多管齐下的策略，平衡供应韧性、与临床机构的合作以及商业性弹性。加强与血浆采集网路的上游伙伴关係，并投资区域血浆分离能力，可以缩短前置作业时间，同时减轻贸易中断和关税的影响。同时，透过投资改进配方和分析技术来增强产品差异化，将有助于提高处方集采纳率，并促进其在住院和门诊病人环境中的应用。

一个严谨的混合方法研究框架，结合专家访谈、监管分析和供应链情境分析方法，以检验关键发现。

本研究途径结合了多方面的证据基础和系统检验，以确保获得可靠的知识和可操作的见解。主要研究包括对血液科、免疫科和神经科的临床医生、公立和私立医院的采购经理和药房主任以及血浆采集和分离机构的高级管理人员进行详细访谈。这些对话提供了关于临床实践、合约趋势和营运限制的详细观点，并用于检验从二手资讯中观察到的趋势。

整合不断变化的临床、运作和政策因素，这些因素决定了免疫球蛋白疗法的可及性、安全性和治疗价值。

静脉注射免疫球蛋白仍然是治疗多种免疫、血液和神经系统疾病的基石治疗方法，但其研发、采购和交付环境正在迅速变化。儘管生产技术的进步和更严格的监管要求提高了产品品质和安全性，但供应链策略的转变和区域生产能力的变化正在重塑免疫球蛋白的获取途径。临床医生、保险公司和医疗保健系统将越来越重视循证用药、透明的来源资讯和可靠的采购管道，以确保治疗的连续性。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：静脉注射免疫球蛋白市场：依产品类型划分

  • 高纯度免疫球蛋白
  • 正常免疫球蛋白
    • 液体
    • 冷冻干燥

第九章：依病患类型分類的静脉注射免疫球蛋白市场

  • 成人版
  • 老年人
  • 儿童

第十章：静脉注射免疫球蛋白市场：依适应症划分

  • 自体免疫疾病
    • Guillain-Barré二氏症候群
    • 免疫性血小板缺乏紫斑症
    • 川崎病
  • 血液疾病
  • 免疫力缺乏
    • 原发性免疫力缺乏
    • 次发性免疫力缺乏
  • 神经系统疾病
    • 慢性脱髓鞘多发性神经炎
    • 多灶性运动神经病变

第十一章 静脉注射免疫球蛋白市场：依最终使用者划分

  • 居家医疗
  • 医院
    • 私立医院
    • 公立医院
  • 专科诊所
    • 血液科诊所
    • 免疫诊所
    • 神经科诊所

第十二章 静脉注射免疫球蛋白市场：依通路划分

  • 直销
  • 医院药房
  • 零售药房
  • 批发商

第十三章 静脉注射免疫球蛋白市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 静脉注射免疫球蛋白市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 静脉注射免疫球蛋白市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国静脉注射免疫球蛋白市场

第十七章：中国静脉注射免疫球蛋白市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Baxter International Inc.
  • Bio Products Laboratory Limited
  • Biotest AG
  • CSL Limited
  • Grifols, SA
  • Johnson & Johnson Services, Inc.
  • Kedrion SpA
  • LFB SA
  • Octapharma AG
  • Option Care Health, Inc.
  • Shanghai RAAS Blood Products Co., Ltd.
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-FF012EDC38B0

The Intravenous Immunoglobulin Market was valued at USD 14.35 billion in 2025 and is projected to grow to USD 15.42 billion in 2026, with a CAGR of 7.72%, reaching USD 24.15 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 14.35 billion
Estimated Year [2026] USD 15.42 billion
Forecast Year [2032] USD 24.15 billion
CAGR (%) 7.72%

A clear, authoritative framing of how intravenous immunoglobulin underpins modern immunotherapy across diverse clinical settings and evolving regulatory expectations

Intravenous immunoglobulin occupies a central role in modern immunotherapy, serving as a critical therapeutic modality across a diverse set of clinical indications. Clinicians rely on these plasma-derived preparations to modulate immune responses in autoimmune, hematological, immunodeficiency, and selected neurological disorders. In contemporary practice, intravenous immunoglobulin is valued both for its broad mechanism of action and for its adaptability across inpatient, outpatient, and specialty care settings, making it a product class that intersects clinical urgency and long-term disease management.

Recent advances in manufacturing and quality control have elevated product consistency and safety profiles, while regulatory scrutiny and supply chain dynamics continue to shape access and utilization. The therapeutic landscape is being influenced by evolving clinical guidelines, greater emphasis on evidence-based use, and the integration of novel indications supported by emerging clinical data. As a result, stakeholders from clinicians to procurement leaders need nuanced insights into how clinical practice, manufacturing scale, and distribution channels interact to determine availability, therapeutic sequencing, and patient outcomes.

How manufacturing innovation, clinical guideline refinement, and regulatory emphasis on traceability are reshaping supply chains and therapeutic use of intravenous immunoglobulin

The intravenous immunoglobulin landscape is undergoing transformative shifts driven by advances in manufacturing, changing clinical practice, and heightened regulatory emphasis on product provenance. New manufacturing approaches and improvements in purification and formulation have reduced adverse event profiles and enabled longer shelf life and more stable liquid presentations, which in turn influence hospital formulary decisions and outpatient administration models. Concurrently, clinicians are refining indications and dosing strategies based on accumulating real-world evidence, prompting tighter alignment between clinical guidelines and utilization.

Supply chain resilience has become a strategic priority as plasma sourcing, donor recruitment, and international logistics face increasing scrutiny. This has spurred vertical integration, strategic partnerships between plasma suppliers and manufacturers, and investment in regional processing capacity. Regulatory agencies are emphasizing traceability and pathogen safety, and health systems are responding with more rigorous procurement standards and contingency planning. Collectively, these shifts are altering where and how intravenous immunoglobulin is produced, distributed, and administered, pressing industry participants to innovate across clinical, operational, and commercial domains.

The cascading effects of tariff changes on global plasma sourcing, production economics, and procurement resilience for immunoglobulin therapies

The imposition of tariffs and related trade measures can have a cascading influence on a global therapeutic class that depends heavily on cross-border plasma procurement and international manufacturing networks. Tariff adjustments affecting inputs, packaging materials, or finished products introduce additional cost pressure that procurement teams and hospital pharmacies must manage, and they can prompt manufacturers to re-evaluate sourcing strategies and contractual structures with suppliers and distributors. In response, firms may pursue localized production or diversify supplier bases to reduce exposure to a single trade regime.

Beyond immediate cost implications, tariffs influence contract negotiations and long-term strategic choices. They may accelerate moves toward regionalization of supply chains, encourage investments in domestic plasma collection and fractionation, or alter the economics of exporting finished product. Payers and hospital systems may shift purchasing patterns to prioritize products with more predictable landed costs, and manufacturers might adapt pricing structures or absorb a portion of tariff-related expenses to maintain competitive positioning. Ultimately, tariffs reshape the calculus around procurement resilience, supplier relationships, and regional manufacturing footprints in ways that require proactive commercial and operational adjustments.

Comprehensive segmentation analysis linking care settings, product formulations, patient demographics, distribution channels, and clinical indications to access dynamics

A granular view of segmentation reveals where clinical demand, formulation preferences, and channel dynamics intersect to shape utilization patterns. End-user considerations span home care, hospital, and specialty clinic settings, with hospitals further differentiated into private and public institutions and specialty clinics segmenting into hematology, immunology, and neurology practices. These distinctions matter because administration setting influences dosing logistics, monitoring requirements, and contracting approaches; private hospitals and specialty clinics often negotiate different reimbursement and procurement terms than public hospitals, and home care requires coordination with nursing services and cold-chain delivery.

Product-type segmentation distinguishes high purity immunoglobulin from standard preparations, and among standard products the formulation choice between liquid and lyophilized options affects storage, reconstitution workflow, and suitability for different care settings. Patient type segmentation identifies adult, geriatric, and pediatric populations, each with unique dosing paradigms and safety considerations that influence clinical protocols and payer coverage decisions. Distribution channel segmentation captures direct sales, hospital pharmacy supply, retail pharmacy dispensing, and wholesale distribution pathways, reflecting how procurement, inventory management, and service-level agreements vary across stakeholders. Indication-based segmentation encompasses autoimmune diseases, hematological conditions, immunodeficiency disorders, and neurological disorders, with autoimmune subcategories such as Guillain-Barre syndrome, immune thrombocytopenic purpura, and Kawasaki disease; hematological focus on hemolytic disease of the newborn; immunodeficiency subtypes including primary and secondary forms; and neurological emphasis on chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy. Integrating these segmentation lenses clarifies where clinical demand concentrates, how supply models must adapt, and which channels are most critical for timely patient access.

Regional dynamics driving supply chain resilience, regulatory rigor, and clinical adoption patterns across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics shape how therapies move from donor plasma to patients, and each macro-region presents distinct regulatory, logistical, and demand-side factors. In the Americas, established plasma collection infrastructure, strong clinician familiarity with intravenous immunoglobulin indications, and advanced hospital settings support broad utilization, while regional payer policies and procurement frameworks influence product selection and contracting approaches. Differences between public and private systems, the role of specialized clinics, and the density of outpatient infusion services all affect how therapies are administered and reimbursed across the region.

Europe, Middle East & Africa present a heterogeneous landscape where regulatory harmonization efforts coexist with national pricing and reimbursement variability. Several countries in this region emphasize stringent traceability and pathogen safety requirements, and both public procurement mechanisms and private specialty networks play roles in access. Investment in regional fractionation capacity and growing attention to supply security are shaping strategic priorities. In Asia-Pacific, rapid healthcare infrastructure expansion, rising clinical adoption across tertiary centers, and increasing investment in plasma collection capacity are notable. However, challenges persist related to distribution logistics, cold-chain reliability, and alignment between clinical guideline adoption and payer coverage. Taken together, regional differences influence manufacturer strategy, clinical adoption timelines, and the design of distribution partnerships to ensure consistent patient access.

How strategic investments in plasma sourcing, manufacturing scale, and clinical evidence are differentiating leading producers and distribution partners

Key industry participants are navigating a complex environment that rewards scale, supply security, and regulatory compliance. Leading firms are investing in upstream plasma sourcing, expanding fractionation capacity, and enhancing pathogen reduction and analytical testing to strengthen product safety and consistency. Strategic alliances between plasma collection networks and manufacturers are increasingly common, aiming to secure raw material streams and reduce exposure to supply disruptions. At the same time, companies are differentiating through formulation advances, portfolio breadth across indications, and value-added services such as patient support programs and infusion center partnerships.

Competitive dynamics also reflect varied go-to-market models: some organizations emphasize direct sales to large hospital systems and integrated health networks, while others prioritize distribution via hospital pharmacies, retail channels, or wholesale partners to reach a broader clinical base. Mergers, targeted acquisitions, and technology partnerships that improve manufacturing yield or reduce cycle time are shaping the competitive map. Additionally, a focus on evidence generation, real-world outcomes studies, and targeted clinical programs is enhancing payer conversations and supporting label expansions or guideline inclusion for new and established indications.

Practical strategic moves for manufacturers and suppliers to secure supply chains, strengthen clinical access, and optimize commercial channel alignment

Industry leaders should adopt a multidimensional strategy that balances supply resilience, clinical engagement, and commercial agility. Strengthening upstream partnerships with plasma collection networks and investing in regional fractionation capabilities will reduce exposure to trade disruptions and tariffs while improving lead times. Simultaneously, enhancing product differentiation through formulation improvements and investment in analytical methods will support formulary positioning and facilitate adoption across inpatient and outpatient settings.

Commercially, organizations should tailor channel strategies to account for differences in direct hospital procurement, hospital pharmacy distribution, retail dispensing, and wholesale networks, and align contracting and value propositions with the specific needs of private versus public institutions and specialty clinics. Clinically, partnering with key opinion leaders across hematology, immunology, and neurology to build robust real-world evidence can accelerate guideline adoption and clarify appropriate utilization across adult, geriatric, and pediatric populations. Finally, firms should implement dynamic pricing and risk-sharing mechanisms that address payer concerns while preserving access, and maintain transparent communication with regulators and health systems to anticipate policy shifts and ensure uninterrupted patient care.

A rigorous mixed-methods research framework blending expert interviews, regulatory analysis, and supply-chain scenario techniques to validate key insights

The research approach combined a multi-source evidence base with structured validation to ensure robust findings and actionable insights. Primary research included in-depth interviews with clinicians across hematology, immunology, and neurology specialties, procurement leaders from private and public hospitals, pharmacy directors, and senior executives in plasma collection and fractionation organizations. These conversations provided granular perspectives on clinical practice, contracting dynamics, and operational constraints, and were used to validate trends observed in secondary sources.

Secondary research encompassed peer-reviewed clinical literature, regulatory guidance documents, manufacturing quality standards, and publicly available filings and technical materials. Analytical methods integrated qualitative synthesis of stakeholder interviews with process mapping of supply chains, scenario analysis of trade and tariff impacts, and comparative review of formulation and distribution models. Quality assurance steps included cross-validation of interview findings against regulatory and clinical literature, internal expert review, and methodological transparency about data limitations and potential biases. This layered approach ensured the report's conclusions rested on convergent evidence and practitioner-informed interpretation.

Synthesis of the evolving clinical, operational, and policy drivers that will determine access, safety, and therapeutic value for immunoglobulin therapies

Intravenous immunoglobulin remains a cornerstone therapy across a range of immunologic, hematologic, and neurologic indications, but the environment in which it is developed, sourced, and delivered is evolving rapidly. Manufacturing advances and tighter regulatory expectations have improved product quality and safety, while shifts in supply chain strategy and regional capacity are reshaping access dynamics. Clinicians, payers, and health systems will increasingly demand evidence-aligned use, transparent provenance, and resilient procurement pathways to ensure continuity of care.

Looking ahead, stakeholders who proactively invest in secure plasma sourcing, flexible manufacturing footprints, and rigorous clinical evidence generation will be best positioned to navigate tariff pressures, distribution complexities, and shifting care models. Cross-sector collaboration among manufacturers, plasma collection networks, clinicians, and payers will be essential to sustain availability and to optimize therapeutic value for patients across diverse care settings and regions.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Intravenous Immunoglobulin Market, by Product Type

  • 8.1. High Purity Immunoglobulin
  • 8.2. Normal Immunoglobulin
    • 8.2.1. Liquid
    • 8.2.2. Lyophilized

9. Intravenous Immunoglobulin Market, by Patient Type

  • 9.1. Adult
  • 9.2. Geriatric
  • 9.3. Pediatric

10. Intravenous Immunoglobulin Market, by Indication

  • 10.1. Autoimmune Diseases
    • 10.1.1. Guillain-Barre Syndrome
    • 10.1.2. Immune Thrombocytopenic Purpura
    • 10.1.3. Kawasaki Disease
  • 10.2. Hematological Conditions
  • 10.3. Immunodeficiency Disorders
    • 10.3.1. Primary Immunodeficiency
    • 10.3.2. Secondary Immunodeficiency
  • 10.4. Neurological Disorders
    • 10.4.1. Chronic Inflammatory Demyelinating Polyneuropathy
    • 10.4.2. Multifocal Motor Neuropathy

11. Intravenous Immunoglobulin Market, by End User

  • 11.1. Home Care
  • 11.2. Hospital
    • 11.2.1. Private Hospital
    • 11.2.2. Public Hospital
  • 11.3. Specialty Clinic
    • 11.3.1. Hematology Clinic
    • 11.3.2. Immunology Clinic
    • 11.3.3. Neurology Clinic

12. Intravenous Immunoglobulin Market, by Distribution Channel

  • 12.1. Direct Sales
  • 12.2. Hospital Pharmacy
  • 12.3. Retail Pharmacy
  • 12.4. Wholesale Distributor

13. Intravenous Immunoglobulin Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Intravenous Immunoglobulin Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Intravenous Immunoglobulin Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Intravenous Immunoglobulin Market

17. China Intravenous Immunoglobulin Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Baxter International Inc.
  • 18.6. Bio Products Laboratory Limited
  • 18.7. Biotest AG
  • 18.8. CSL Limited
  • 18.9. Grifols, S.A.
  • 18.10. Johnson & Johnson Services, Inc.
  • 18.11. Kedrion S.p.A.
  • 18.12. LFB S.A.
  • 18.13. Octapharma AG
  • 18.14. Option Care Health, Inc.
  • 18.15. Shanghai RAAS Blood Products Co., Ltd.
  • 18.16. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HIGH PURITY IMMUNOGLOBULIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HIGH PURITY IMMUNOGLOBULIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HIGH PURITY IMMUNOGLOBULIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY LIQUID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY LIQUID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY LIQUID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY LYOPHILIZED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY LYOPHILIZED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY LYOPHILIZED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY GUILLAIN-BARRE SYNDROME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY GUILLAIN-BARRE SYNDROME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY GUILLAIN-BARRE SYNDROME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNE THROMBOCYTOPENIC PURPURA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNE THROMBOCYTOPENIC PURPURA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNE THROMBOCYTOPENIC PURPURA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY KAWASAKI DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY KAWASAKI DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY KAWASAKI DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGICAL CONDITIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGICAL CONDITIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGICAL CONDITIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY MULTIFOCAL MOTOR NEUROPATHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY MULTIFOCAL MOTOR NEUROPATHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY MULTIFOCAL MOTOR NEUROPATHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIVATE HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIVATE HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIVATE HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PUBLIC HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PUBLIC HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PUBLIC HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNOLOGY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNOLOGY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNOLOGY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY WHOLESALE DISTRIBUTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY WHOLESALE DISTRIBUTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY WHOLESALE DISTRIBUTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 200. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. ASEAN INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. ASEAN INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 206. ASEAN INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 213. GCC INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. GCC INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. GCC INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 216. GCC INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. GCC INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 218. GCC INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 219. GCC INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 220. GCC INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 221. GCC INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. GCC INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 223. GCC INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 224. GCC INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPEAN UNION INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPEAN UNION INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPEAN UNION INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPEAN UNION INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPEAN UNION INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPEAN UNION INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPEAN UNION INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPEAN UNION INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPEAN UNION INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 238. BRICS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. BRICS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 240. BRICS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. BRICS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 242. BRICS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 243. BRICS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 244. BRICS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 245. BRICS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 246. BRICS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 247. BRICS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 248. BRICS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 249. G7 INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 250. G7 INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. G7 INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 252. G7 INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. G7 INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 254. G7 INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 255. G7 INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 256. G7 INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 257. G7 INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 258. G7 INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 259. G7 INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 260. G7 INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 261. NATO INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 262. NATO INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. NATO INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 264. NATO INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. NATO INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 266. NATO INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 267. NATO INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 268. NATO INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 269. NATO INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 270. NATO INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 271. NATO INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 272. NATO INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 273. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 274. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 275. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 276. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 277. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 278. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 279. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 280. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 281. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 282. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 283. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 284. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 285. UNITED STATES INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 286. CHINA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 287. CHINA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 288. CHINA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 289. CHINA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 290. CHINA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 291. CHINA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 292. CHINA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 293. CHINA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 294. CHINA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 295. CHINA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 296. CHINA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 297. CHINA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)